The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial

Ali Esfahani¹, Mohammad hossein Somi¹, Hormoz Ayromlou², Alireza Nikanfar³, Mohammad Asghari Jafarabadi⁴, Bina Eftekhar Sadat⁵ and Zohreh Ghoreishi⁶*

Abstract

Background: Oxaliplatin induced peripheral neurotoxicity (OXIPN) is the major dose-limiting and long-lasting side effect of oxaliplatin. N-3 PUFAs have neuroprotective property via their effects on voltage-gated ion channels and by reducing the production of proinflammatory cytokines that causes neuropathy. This study was a randomized double blind placebo controlled trial to find the possible advantages of n-3 PUFAs for preventing and reducing the severity of OXIPN in patients with colon cancer.

Methods: Eligible patients with colon cancer randomly allocated to take n-3 PUFAs pearls, 640 mg t.i.d during chemotherapy with oxaliplatin and one month after the cessation of the treatment or placebo. All patients were evaluated for incidence and severity of OXIPN based on “reduced Total Neuropathy Score” in which clinical and electrophysiological assessments were included.

Results: Seventeen patients (47 %) of the n-3 PUFA supplemented group (n = 36) did not develop PN while it was 11 %(4 patients) in the placebo group (n = 35). There was a significant difference in PN incidence (OR = 0.14, 95 % CI = (0.04 to 0.49), p = 0.002). The difference of OXIPN severity was significant between the two study groups (B = −1.61, 0.95 % CI = (−2.59 to −0.62), p = 0.001).

Conclusions: N-3 PUFAs may have neuroprotective effect for reducing the incidence and severity of OXIPN. Finding an effective prophylactic or symptomatic therapy for OXIPN would significantly improve the patients’ quality of life.

Keywords: Colon cancer, n-3 polysaturated fatty acids, Oxaliplatin, Neuropathy
the efficacy of n-3 PUFAs for prophylaxis against paclitaxel-induced peripheral neuropathy in patients with breast cancer [14].

The possible advantages of n-3 PUFAs for preventing and reducing the severity of OXIPN in patients with colon cancer were assessed in the present study that is the first attempt in this area. As CRC survivors are the third largest population of cancer survivors [2, 5, 13], attenuating the risk of OXIPN- the major factor that decreases their quality of life- is now a major concern. Moreover, the serum level of proinflammatory cytokines was measured for assessing their changes during supplementation with n-3 PUFAs.

Methods

Primary outcome

This randomized double-blind placebo-controlled trial was conducted to assess the effect of n-3 PUFAs on incidence and severity of OXIPN in patients with colon cancer undergoing chemotherapy with oxaliplatin.

Patients

From February 2012 to January 2015, male or female patients with confirmed stage III colon cancer, aged between 20 and 85 years, and treated at Sheikhorrais University Clinic with oxaliplatin, 130 mg/m$^2$ IV, administered over 2 h infusion in day 1 and oral capecitabine (1000 mg/m$^2$, b.i.d) on days 1–4, to be repeated every 3 weeks for 8 cycles, were enrolled. Other inclusion criteria of the study were WHO performance status score of 0-1, and normal kidney and liver function.

Patients were excluded from the study if they had pre-existing peripheral neuropathy (PN) due to diabetes mellitus, alcoholic disease, HIV, and inherited PN- associated disorders. Patients who received other neurotoxic drugs prior to oxaliplatin therapy or those who were on any form of supplement therapy (fish oil, vitamins and minerals) were also excluded from the study.

Intervention and randomization

Eligible patients were randomly allocated in a 1:1 ratio to receive n-3 PUFAs pearls (Mor DHA Mini I.Q. Minami Nutrition NV, Drie Eikenstraat 661, 2650 Edegem, Belgium) at a dose of 640 mg (54 % DHA, 10 % EPA) three times a day coinciding with the start of chemotherapy until one month after the end of treatment or placebo pearls containing sun flower oil (Dana Pharma, Tabriz, Iran). Placebo and n-3 PUFAs pearls were similar in appearance and color and administered based on the same protocol.

Random allocation software (RAS) version 1.0.0. (Esfahan, Iran) was used for Permuted block randomization to assign patients to either the n-3 PUFAs supplemented group or the control group. Only the randomization coordinator of the study was aware of the patients’ allocations.

Neurologic evaluation

All patients were evaluated prior to chemotherapy and one month after the cessation of treatment (about 25 weeks) by the same neurologist who carried out both clinical and electrophysiological assessments. He was blinded to the patient’s allocation to study groups.

The presence of chronic OXIPN and grading of its severity was ascertained by reduced Total Neuropathy Score (TNSr) as the primary outcome measures. TNSr is an easy to use composite scale for assessing chemotherapy-induced peripheral neuropathy (CIPN) [15]. Subjective sensory symptoms, pin sensibility, deep tendon reflexes, and sural and peroneal amplitude (a total of 7 parameters) are all included in TNSr. Each parameter has a score from 0 to 4, based on the measured severity; then the total score ranges from 0 to 28 that grades OXIPN as follows: grade 0, no OXIPN, 1–10, mild; 11–19, moderate; and 20–28, severe OXIPN [14].

Secondary outcome

a) Nerve conduction studies (NCVs)

Electrophysiological studies were carried out unilaterally (right side) under a uniform protocol using a Nicolet/VIASYS Viking Quest EMG Machine [16]. Thirty-two to 34°C was set as the distal skin temperature. The estimated parameters included: Distal motor latency (DML), peak to baseline amplitude of compound muscle action potential (a-CMAP), and motor conduction velocity for tibial, Peroneal and ulnar nerves. Moreover, peak-to-peak amplitude of sensory action potentials (a-SAP) and sensory conduction velocity (antidromic technique) of sural and ulnar nerves were also measured.

b) Proinflammatory cytokines

Serum levels of proinflammatory cytokines: interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-$\alpha$), and high-sensitivity C-reactive Protein (hs-CRP) were measured before the onset of chemotherapy and one month after the cessation of treatment by Human IL-6 Platinum ELISA, Human TNF alpha Platinum ELISA (eBioscience, INC. San Diego, CA 92121, USA) and Minineph™ Human kits (Birmingham, UK) respectively.

Protocol approvals and patient consent

This study (IRCT201112158397N2) was approved by the Ethics Committee of Tabriz University of Medical Sciences (No: 5/4/10130) and informed consent was
obtained from all the study subjects before any intervention.

**Statistical analysis**

Data have been shown using mean (SD) and frequency (percent) for quantitative and qualitative variables respectively. To define the differences of nerve conduction measurements, analysis of covariance was used adjusting baseline measurements. Logistic regression analysis was performed to find the difference of OXIPN incidence between the two groups, estimating the odds ratio. Ordinal regression analysis was done to compare the severity of OXIPN. All tests were two-tailed and significance level was determined 0.05. For analyzing the results on an intention to treat (ITT) basis, multiple imputation was performed by related variables. Statistical power of the study was 80% and all analysis was done using spss software, (spss Inc., Chicago, IL).

**Sample size**

To determine the sample size, primary information was obtained from the study by Ghoreishi et al. In this study, the protective effect of n-3 PUFAs against paclitaxel-induced neuropathy in patients with breast cancer was assessed. Using odds ratio (OR) = 0.3, α = 0.05, a power of 80 %, and two-tailed analysis and G Power software (Franz Foal, Kiel University, Germany), the minimum sample size was estimated 38 subjects and after considering 30 % lost to follow up, it was increased to 50.

**Results**

**Patients**

Among the 84 recruited patients, 13 patients were excluded from the study due to diabetes mellitus, declined to participate, and taking some kinds of oral supplements (Fig. 1). Therefore, 71 patient were randomly allocated to receive n-3 PUFAs (n = 36, 50 % male with the average of age and BMI as: 54.14 ± 10.53 & 23.47 ± 3.40 kg/m² respectively) or placebo (n = 35, 60 % male, with the average of age and BMI as: 53.40 ± 15.70 & 23.22 ± 4.77 kg/m² respectively). There was not any statistical difference between two groups in terms of gender, age, and BMI (P = .477, .816, and .806 respectively, Table 1). The rate of drop out was 5 patients in n-3 PUFAs supplemented group and 7 patients in the placebo group (Fig. 1), so the response rate was 80.09 %. Data of the main outcome (incidence and severity of OXIPN), was divided into 2 categories: code 1 allocated to missing and code 2 allocated to valid observations. Then demographic variables were compared between ITT patients and efficacy population. Accordingly, they were not statistically different in terms of age (P = 0.658), BMI (P = 0.224) and gender (P = 0.354).

All patients suffered from metastatic colon cancer (stage III) and they treated with oxaliplatin, 130 mg/m² IV, administered over 2 h infusion in day 1 and oral capecitabine (1000 mg/m², b.i.d) on days 1–4, to be repeated every 3 weeks for 8 cycles. No patient received radiation therapy. The patients of the two groups were equivalent regarding the treatment protocol.

**Assessment of OXIPN**

One month after the cessation of chemotherapy, 17 patients (47 %) did not develop OXIPN in n-3 PUFAs supplemented group while the remaining 19 patients manifested some grade of neurotoxicity based on TNSr: mild OXIPN in 15 (42 %) patients; moderate and severe OXIPN in 1 (3%) and 3 (8%) patients respectively. In placebo group, OXIPN was disclosed in 31 (88 %) of the patients: mild OXIPN in 20 patients (57 %), moderate and severe OXIPN in 7 patients (20 %) and 4 patients (12 %) respectively (Fig. 2). A significant difference was observed between the two groups in OXIPN incidence (OR = 0.14, .95 % CI = (0.04 to 0.49), p = 0.002). So group I had 86 % lower risk of PN incidence. The number needed to treat (NNT) to prevent one PN event was 2, and absolute risk reduction (ARR) for supplemented group compared with the control group was 0.41 (0.16 to 0.59). Remarkably, there were a statistically significant difference in severity of OXIPN between these two groups (B = −1.61, .95 % CI = (−2.59 to −.62), p = 0.001). Adjusting for age, the differences between incidence and severity of OXIPN were more significant [(OR = 0.11, .95 % CI = (0.07 to 0.16), p = 0.001); (B = −1.74, .95 % CI = (−2.74 to −.75), p = 0.001)].

**Nerve conduction studies**

Significant statistical changes were observed between two study groups in terms of tibial and ulnar motor a-CMAP at one month after the cessation of chemotherapy (Table 2). However, the percent change measured (final measures versus the baseline values) showed that the deterioration of tibial, and ulnar a-CMAP was considerable in placebo group while they were increased in the. Moreover, the increase of peroneal nerve a-CMAP in the n-3 PUFAs group was much more than the increase in the placebo group (Table 2).

There was not a statistically difference between the two study groups according to sensory conduction studies, although a considerable trend for the differences of sural a-SAPs was observed between the two groups. The percent change of both sural and ulnar nerves’ a-SAP showed a considerable decrease however, the decrease of the a-SAPs was strongly more pronounced in the placebo group at one month after the cessation of chemotherapy (Table 3).
**Proinflammatory cytokines**

At the end of supplementation period (one month after the cessation of chemotherapy), the serum levels of IL-6 and TNF-α decreased 20.91 and 12.50 % respectively in the n-3 PUFAs group while they were increased in the placebo group without statistically significant differences. The serum level of hs-CRP was decreased in both groups although it was further reduced in the placebo group (61.02 % vs. 55.21 %, Table 4).

**Discussion**

We assessed the efficacy of n-3 PUFAs, mainly DHA, for preventing and reducing the severity of OXIPN in patients with colon cancer. Patients undergoing chemotherapy with oxaliplatin (XELOX regimen) randomly assigned to receive n-3 PUFAs pearls or placebo during the treatment courses and one month after the cessation of therapy (about 25 weeks) while incidence and severity of OXIPN were assessed in both time. This study showed that n3- PUFAs are protective against OXIPN in patients with colon cancer. Here we focused solely on chronic OXIPN that is a sensory-motor axon loss and the major dose-limiting side effect of oxaliplatin. It begins at a cumulative dose of 750–850 mg/m² and may be continued for a long time after the end of treatment [7, 17].

Clinical and electrophysiological finding were summarized by TNSr [15, 18] (ranging 0 to 28). It can be easily used for determining the incidence and severity of CIPN and it has a significant correlation with the known oncologic toxicity scales such as NCI-CTC, Ajani and ECOG scales, and the complete version of TNS as...
well [14, 15]. It is an effective easy-to-use alternative for TNS.

Nerve conduction studies can assess the extent of chemotherapy-induced peripheral neuropathy objectively and are also capable of identifying patients with subclinical neuropathy before the manifestation of clinically significant peripheral neuropathy [19]. In this study, the a-CMAPs of all three tibial, peroneal and ulnar motor nerves, were increased in proportion to the baseline values in the n-3 PUFA group, while they decreased in the placebo group (except for peroneal nerve which also increased slightly in the placebo group) without statistically difference between two groups probably due to small sample size (Table 2). Notably, the change percent of a-CMAPs in motor nerves was much less than 50% indicating that OXIPN is more sensory than motor neuropathy. The a-SAPs of sural and ulnar nerves were decreased in proportion to the baseline values in both the n-3 PUFA and placebo groups. However, the decrease in a-SAP was much greater in the latter group (Table 3). Argyriou et al. reported that the only independent predictor for unfavorable neurological outcomes was the decrease of sural a-SAP >50% in proportion to the baseline values in cancer patients undergoing treatment with cisplatin and paclitaxel [18]. In this study, DHA helped prevent a sharp reduction in sural (~36.68% vs. ~100.00%) and ulnar (~18.28% vs. ~42.06%) a-SAPs in the n-3 PUFA supplemented group and it improved the a-CMAP of tibial, peroneal and ulnar motor nerves indicating the beneficial effects of n-3 PUFA (particularly DHA) on both sensory and motor nerve conduction parameters.

Recently, dysfunction of axonal membrane Na$^+$ and Ca$^{2+}$ channels have been proposed as one of the mechanisms underlying OXIPN as well as pain related to chronic neuropathy [20, 21]. Therefore, finding an agent capable of modulating ion channel activity may be effective in preventing and reducing OXIPN, as some evidences suggested that calcium channel blockers could reduce acute OXIPN in patients receiving modified FOLFOX chemotherapy regimen [22]. Previous studies have shown that the anti-hypertensive as well as antiarrhythmic properties of n-3 PUFA are due to their ability to block voltage-gated sodium channels (VGSCs) and voltage-gated calcium channels (VGCCs) reversibly in arteries of muscle cells and cardiomyocytes without frequency-dependent resistance [9, 23, 24]. N-3 PUFA can also block L-type VGCC and VGSCs of the pain neurons involved in neuropathic pain as well [9]. Some studies revealed that an infusion of oxaliplatin in CRC patients caused the release of inflammatory cytokines such as interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) [25, 26] Interleukin-1beta (IL-1β), IL-6 and TNF-α (proinflammatory cytokines) and prostaglandin E2 (PGE2) as an eicosanoid develop neuropathic and inflammatory pain by their direct and indirect impact on the central and peripheral nervous systems (including DRG neurons, and glial cells) [9]. Moreover, IL-1β and TNF-α contribute to the rapid excitation of nociceptors via the induction of Cyclooxygenase 2 (COX-2) [27]. Serum levels of IL-6 and TNF-alpha were decreased in n-3 PUFA supplemented group, although there was not a statistical difference with placebo, possibly due to low dose and relatively short period of n-3 PUFA supplementation.

DHA has anti-neuroinflammatory properties both in central and peripheral nervous system and it has been attributed to the DHA efficacy in the prevention and treatment of neurodegenerative disorders such as major depression, Alzheimer’s and Parkinson’s diseases. Neuroprotectin D1 (NPD1) is synthesized from DHA in the body and it is an effective neuroprotective agent for the prevention and treatment of confirmed neuropathic pain. Noteworthy, the repeated administration of opioids may cause antinociceptive drug tolerance and even hyperalgesia, but DHA-derived NPD1 do not create such

---

Table 1 General characteristics of the patients

| Group                  | n-3 PUFAs (n = 36) | Placebo (n = 35) | P value |
|------------------------|--------------------|-----------------|---------|
| Gender (%)             |                    |                 |         |
| Male                   | 50                 | 60              | .477**  |
| Female                 | 50                 | 40              | .816**  |
| Age (Year, mean ± SD)  |                    |                 |         |
| Male                   | 54.14 ± 10.53      | 53.40 ± 15.70   | .816**  |
| Female                 | 58.22 ± 8.02       | 54.48 ± 16.56   |         |
| BMI (kg/m$^2$, mean ± SD) |                |                 |         |
| Male                   | 23.47 ± 3.40       | 23.22 ± 7.77    | .806**  |
| Female                 | 22.43 ± 2.94       | 22.26 ± 2.91    |         |
| BMI                     | 24.54 ± 4.68       | 24.91 ± 6.77    |         |

*P value is reported based on exact Chi-square test
**P value is reported based on Independent-Samples T Test

*Body mass index
a resistance even after a long-term use of DHA [28–30]. It can promote axonal regeneration after chemotherapy-induced peripheral neuropathy as a nerve growth factor. NPD1 reduces gene expression of proinflammatory cytokines (IL-1β and TNF-α) and COX-2 as well. Serum levels of IL-6 and TNF-alpha were decreased in n-3 PUFAs supplemented group, although there was not a statistical difference with placebo, possibly due to low dose and relatively short period of n-3 PUFAs supplementation.

In a number of randomized controlled trials using n-3 PUFAs, the rate of adverse events was not greater than 5 % with no considerable difference in frequency with placebo groups and only some GI discomforts like nausea and a fishy burp were reported. The standardized preparation of n-3 PUFAs is in the capsular form and it can be taken without considerable concern for interaction with other medications. We recommended to our patients to take n-3 PUFAs capsules with meals and keep them in the refrigerator. They had a strawberry

| Table 2 Comparing the motor nerve conduction measurements between the two study groups |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
|                                | n-3 PUFAs (Mean ± SD) | Placebo (Mean ± SD) | Mean Difference | 95 % CI, P-value |
| Tibial nerve                   |                                |                               |                |
| DML 1 (ms)                     | 4.82 ± .81                  | 5.80 ± 1.31                  | −.98           | −1.50 to −.46, <.001* |
| DML 2                          | 4.60 ± .79                  | 5.70 ± .95                   | −.68           | −1.18 to −.12, 0.099** |
| % Change                       | −4.77                       | −1.73                        |                |
| a-CMAP1 (mV)                   | 9.30 (5.62–13.72)           | 10.20 (5.60–15.30)           | −              | .696*** |
| a-CMAP 2                       | 10.20 (6.20–13.00)          | 6.10 (3.47–9.25)             |                | .003b |
| % Change                       | 9.68                        | −40.20                       |                |
| MCV 1 (m/s)                    | 45.81 ± 6.6                | 43.06 ± 5.08                 | 2.74           | −.05 to 5.54, .054* |
| MCV 2                          | 45.67 ± 6.18                | 42.34 ± 4.68                 | 1.86           | −.52 to 4.25, 1.123** |
| % Change                       | −31                         | −1.70                        |                |
| Peroneal nerve                 |                                |                               |                |
| DML 1 (ms)                     | 4.34 ± .92                  | 5.21 ± 1.44                  | −.87           | −1.45 to −.30, 0.004* |
| DML 2                          | 4.16 ± 1.04                 | 5.02 ± 1.95                  | .08            | −.78 to .94, .850** |
| % Change                       | −3.93                       | −3.65                        |                |
| a-CMAP1 (mV)                   | 4.00 (3.00–4.60)            | 2.80 (1.90–3.20)             | −              | .238*** |
| a-CMAP 2                       | 4.40 (3.10–5.30)            | 2.90 (1.70–3.75)             |                | .217b |
| % Change                       | 10.00                       | 3.57                         |                |
| MCV 1 (m/s)                    | 47.59 ± 5.95                | 44.07 ± 6.91                 | 3.51           | .40 to 6.63, .028* |
| MCV 2                          | 44.70 ± 5.30                | 43.60 ± 6.87                 | −1.37          | −3.88 to 1.14, .728** |
| % Change                       | −6.07                       | −1.07                        |                |
| Ulnar nerve                    |                                |                               |                |
| DML 1 (ms)                     | 3.12 ± .61                  | 3.35 ± .59                   | −.23           | −.51 to 0.60, 1.18* |
| DML 2                          | 2.97 ± .55                  | 3.33 ± .59                   | −.26           | −.54 to 0.02, .073** |
| % Change                       | −4.81                       | −.60                         |                |
| a-CMAP1 (mV)                   | 11.85 (9.40–14.30)          | 12.40 (10.80–13.10)          | −              | .394*** |
| a-CMAP 2                       | 13.10 (10.10–15.00)         | 10.75 (10.00–12.60)          |                | .033b |
| % Change                       | 10.55                       | −13.31                       |                |
| MCV 1 (m/s)                    | 63.01 ± 26.22               | 55.60 ± 10.89                | 7.42           | −2.14 to 16.98, .126* |
| MCV 2                          | 53.64 ± 16.72               | 53.98 ± 6.34                 | .07            | −6.84 to 6.97, .984** |
| % Change                       | −14.87                      | −2.90                        |                |

DML distal motor latency, a-CMAP amplitude of compound muscle action potential, MCV motor conduction velocity
*P value is reported based on Independent-Samples T-Test
**P value is reported based on the analysis of covariance, adjusted for baseline values
***P value is reported based on the Mann–Whitney U Test
1*One month after the cessation of chemotherapy
2P value is reported based on the Mann–Whitney U Test (for changes of values during the intervention period)
3Percent change in proportion to the baseline values
taste, and were well tolerated by the patients. The US
Food and Drug Administration (FDA) recommended
maximum levels of 3 g per day of n-3 PUFAs supple-
mentation [31]. In the current study, the total dose of n-
3 PUFAs administered was 1244.1 mg per day (640 mg:54%DHA, 10 % EPA, t.i.d) which was far below the
maximum FDA recommended for more prudence. No
considerable side effects were reported by the patients.

Among a wide variety of compounds assessed for the
prevention or treatment of chemotherapy-induced
neuropathy, including vitamin E [32], Ca- Mg infusion
[33–35], amifostine, glutamine, and glutathione [36], the
Ca- Mg infusion was effective in this field. There is a
corner, however of interference with the clinical effi-
cacy of chemotherapy. Other compounds such as antide-
pressants, anticonvulsants [36] and green tea [37] had
limited effects or they were not studied in RCTs.
Lack of long-term follow up of the patients due to
high cost needed was one of the limitations of this study.
Therefore, coasting phenomenon and self-improvement
after the cessation of chemotherapy was not compared
between the two study groups. Moreover, placebo did
not smell fish oil and it may be considered as another
limitation of this study. Despite the relatively small

### Table 3 Comparing the sensory nerve conduction measurements between the two study groups

|                      | n-3 PUFAs (Mean ± SD) | Placebo (Mean ± SD) | Mean Difference | 95 % CI P-value |
|----------------------|-----------------------|--------------------|----------------|----------------|
| Sural nerve          |                       |                    |                |                |
| aSAP1 (μV)           | 9.95 (5.52–16.40)     | 5.50 (3.40–14.10)  | –              | .033***        |
| aSAP2                | 6.30 (4.60–10.30)     | .00 (0.00–7.32)    | .052           |
| % Change             | –36.68                | –100.00            |                |                |
| SCV1 (m/s)           | 43.99 ± 15.17         | 44.82 ± 6.27       | –.83           | –6.44 to 4.78, .766* |
| SCV2                 | 42.29 ± 15.51         | 29.67 ± 13.01      | 12.24          | 2.22 to 22.26, .018** |
| % Change             | –3.84                 | –33.80             |                |                |
| Ulnar nerve          |                       |                    |                |                |
| aSAP1 (μV)           | 27.90 (16.82–42.77)   | 17.50 (12.40–35.50)| –              | .144***        |
| aSAP2                | 22.80 (6.20–27.30)    | 10.14 (2.70–18.60) | .430           |
| % Change             | –18.28                | –42.06             | .052           |
| SCV1 (m/s)           | 51.66 ± 8.34          | 50.15 ± 8.23       | 1.50           | –2.51 to 5.52, .457* |
| SCV2                 | 44.08 ± 11.14         | 42.62 ± 7.26       | .98            | –4.61 to 6.57, .726** |
| % Change             | –14.66                | –15.01             | .766           |

*a-SAP sensory action potential amplitude, SCV sensory conduction velocity
*P value is reported based on Independent-Samples T-Test
**P value is reported based on the analysis of covariance, adjusted for baseline values
***P value is reported based on the Mann–Whitney U Test
*One month after the cessation of chemotherapy
**P value is reported based on the Mann–Whitney U Test (for changes of values during the intervention period)
*Percent change in proportion to the baseline values

### Table 4 Serum levels of proinflammatory cytokines in two groups of patients

|                      | n-3 PUFAs (Median, percentile 25–75) | Placebo (Median, percentile 25–75) | P-value |
|----------------------|-------------------------------------|-----------------------------------|---------|
| IL-6                 | 28.70 (20.50–42.60)                 | 21.50 (15.20–51.10)               | .194*   |
| IL-6                 | 22.70 (17.10–30.45)                 | 25.50 (16.80–55.40)               | .396**  |
| % Change             | –20.91                              | 18.60                             |         |
| TNF-α                | 4.00 (3.60–5.25)                    | 4.30 (3.60–5.60)                  | .218*   |
| TNF-α                | 3.50 (3.15–4.97)                    | 4.35 (3.15–4.97)                  | .097*** |
| % Change             | –12.50                              | 11.60                             |         |
| hs-CRP               | 2.95 (9.2–7.30)                     | 2.88 (1.31–15.40)                 | .505*   |
| hs-CRP               | 1.15 (82–232)                      | 1.29 (82–290)                    | .390**  |
| % Change             | –61.02                              | –55.21                            |         |

*P value is reported based on the Mann–Whitney U Test
**P value is reported based on the Mann–Whitney U Test (for changes of values during the intervention period)
*Interleukin-6
**Tumor necrosis factor-α
sample size of this study (we could not run a multicenter RCT, because of some problems in coordination between centers), the incidence and severity of OXIPN was different between the n-3 PUFAs and placebo groups, maybe due to the strong effect of DHA on the peripheral nervous system of the patients through the different mechanisms pointed out here and other presently unknown reasons, as the precise mechanism of OXIPN is not clear.

Conclusions

OXIPN will continue for a long time in patients who received oxaliplatin and it has a remarkable influence on the patients' quality of life [1, 7]. As the survival of this group of patients is increased significantly worldwide, finding an effective prophylactic or symptomatic therapy for OXIPN should be of special interest [2, 5]. In this study, n-3 PUFAs supplementation could reduce the incidence and severity of OXIPN in patients with colon cancer. It is well tolerated by patients because of few if any complications. Therefore, given the low-cost and safety of DHA, it can be recommended as a prophylactic and therapeutic agent for OXIPN. Further studies with larger sample size and longer follow-up are needed to confirm these findings.

Abbreviations

a-CMAP, amplitude of compound muscle action potential; a-SAP, sensory action potentials; CIPN, chemotherapy-induced peripheral neuropathy; CRC, colorectal cancer; DHA, docosahexaenoic acid; DML, distal motor latency; EPA, eicosapentaenoic acid; MCV, motor conduction velocity; NCVs, the nerve conduction studies; OXIPN, oxaliplatin-induced peripheral neuropathy; PUFAs, n-3 polyunsaturated fatty acids; TNSr, reduced total neuropathy score

Acknowledgements

The authors thank “Sanofi - IRAN” that was the financial sponsor of this research, grant number: OxiLi_L_06172. The authors are also grateful to Minami Nutrition Company, for kind help to provide n-3 PUFAs pearls. We also thank Dana Pharma Pharmaceutical Company that provided us with placebo pearls.

Funding

This study was funded by “Sanofi” in IRAN.

Authors’ contributions

Ali Esfahani, Mohammad Hossein Somi, Alineza Nikanfar, and Zohreh Ghoreishi were involved in the study design and concept. All Esfahani was responsible for data collection, Hormoz Ayroutmlou and Bina Efehkar Sadat were responsible for neurologic assessment and interpretation, Mohammad Asghari Jafarabadi carried out the statistical analysis and interpretation, Zohreh Ghoreishi was responsible for interpretation of the data and preparing the manuscript. All authors reviewed the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Ethics approval

This study was approved by the Ethics Committee of Tabriz University of Medical Sciences (No: 5/4/10130) and informed consent was obtained from all the study subjects before any intervention.

Author details

1 Gastroenterology, Liver & Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 2 Neurosiences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 3 Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 4 Tabriz Health Services Management Research Center and Department of Statistics and Epidemiology, Faculty of Health and Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran. 5 Physical Medicine & Rehabilitation Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 6 Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Received: 17 April 2016 Accepted: 2 June 2016
Published online: 23 June 2016

References

1. Argyrionia AA, Polychronopoulos P, Iconomidou G, Koutras A, Makatsoris T, Gerolymos MK, Gourzi P, Assimakopoulos K, Kalofonos HP, Chroni E. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol. 2007;46(8):1151–7.
2. Bukagazi AZ, Messersmith W, Vaidya D, Hauer P, Hoke A, Polydefkis M. Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology. 2011;77(10):980–6.
3. de Gramont A, Figuer A, Seymour M, Homerin M, Hmisi A, Cassidy J, Boni C, Cortes-Funes H, Ceravantes A, Freyer G, Leucovorin and Fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):3938–47.
4. André T, Boni C, Mounejdi-Boudifl L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.
5. Bennett BK, Park SB, Lin CSY, Friedlander ML, Kiernan MC, Goldstein D. Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer. 2012;20(11):2959–67.
6. Gamelin E, Gamelin L, Bossi L, Quaashoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. In: Seminars in oncology. 2002. Elsevier; 2002: 21–33.
7. Mois F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Fransen LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 2013. doi: 10.1200/JCO.2013.49.1514.
8. Ventrizel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB. Chemotherapy-induced pain and neuropathy: A prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain. 2016;157(3):560–68.
9. Shapiro H. Could n-3 polyunsaturated fatty acids reduce pathological pain by direct actions on the nervous system? Prostaglandins Leukot Essent Fatty Acids. 2003;68(3):219–24.
10. Mazza M, Pomponi M, Janiri L, Brta P, Maza S. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: an overview. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31(1):12–26.
11. Coste TC, Gerbi A, Vague P, Pieroni G, Raccall D. Neuroprotective effect of docosahexaenoic acid-enriched phospholipids in experimental diabetic neuropathy. Diabetes. 2003;52(10):2578–85.
12. Vosvoky C, Collins M, Abbott L, Aschenbrenner J, Hart C. Putting Evidence Into Practice*: Evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs. 2007;11(6):901–13.
13. Park SB, Lin CSY, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist. 2011;16(5):708–16.
14. Ghoreishi Z, Esfahani A, Diazzaey A, Djabali M, Golestan B, Ayromlou H, Hashemzade S, Jafarabadi MA, Montazeri V, Keshavarz SA. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer. 2012;12(1):355.
15. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Parma G, Cortes-Funes H, Cervantes A, Freyer G, Leucovorin and Fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):3938–47.
16. Cortes-Funes H, Cervantes A, Freyer G. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):3938–47.
17. Serenoa M, Gutiérrez-Gutiérrezb G, Gómez-Raposoa C, Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Fransen LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 2013. doi: 10.1200/JCO.2013.49.1514.
18. Argyriou AA, Polychronopoulos P, Koutras A, Iconomou G, Iconomou A, Kalofonos HP, Chroni E. Peripheral neuropathy induced by administration of cisplatin-and paclitaxel-based chemotherapy. Could it be predicted? Support Care Cancer. 2005;13(8):647–51.
19. Argyriou AA, Polychronopoulos P, Chroni E. The usefulness of nerve conduction studies in objectively assessing oxaliplatin-induced peripheral neuropathy. Oncologist. 2007;12(11):1371–2.
20. Park SB, Krishnan AV, Lin C, Goldstein D, Friedlander M, Kiernan MC. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem. 2008;15(29):3081–94.
21. Fossat P, Dobremez E, Bouali-Benazzouz R, Favereaux A, Bertrand SS, Kilk K, Léger C, Cazalets J-R, Langel U, Landry M. Knockdown of L calcium channel subtypes: differential effects in neuropathic pain. J Neurosci. 2010;30(3):1073–85.
22. Tatsushima Y, Egashira N, Narishige Y, Fukui S, Kawashiri T, Yamauchi Y, Oishi R. Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy. Biomed Pharmacother. 2013;67(1):39–42.
23. Ferrier GR, Redondo I, Zhu J, Murphy MG. Differential effects of docosahexaenoic acid on contractions and L-type Ca2+ current in adult cardiac myocytes. Cardiovasc Res. 2002;54(3):601–10.
24. Vreugdenhil M, Bruehl C, Voskuyl RA, Kang JX, Leaf A, Wadman WJ. Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons. Proc Natl Acad Sci. 1996;93(22):12559–63.
25. Tonini G, Santini D, Vincenzi B, Borzomati D, Dicuonzo G, La Cesa A, Onori N, Coppola R. Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. J Biol Regul Homeost Agents. 2001;16(2):105–9.
26. Boyette-Davis JA, Walters ET, Dougherty PM. Mechanisms involved in the development of chemotherapy-induced neuropathy. Pain Manag. 2015;5(4):285–96.
27. Binshtok AM, Wang H, Zimmermann K, Vardeh D, Shi L, Brenner GJ, Ji R-R, Bean BP, Woolf CJ. Nociceptors are interleukin-1beta sensors. J Neurosci. 2008;28(52):14062–73.
28. Bazan NG, Molina MF, Gordon WC. Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer’s, and other neurodegenerative diseases. Annu Rev Nutr. 2011;31:321.
29. Xu Z-Z, Liu X-J, Berta T, Park C-K, Lu N, Serhan CN, Ji R-R. Neuroprotectin/D1 protects against neuropathic pain in mice after nerve trauma. Ann Neurol. 2013;74(3):490–5.
30. Bazan NG. The docosanoid neuroprotectin D1 induces homeostatic regulation of neuroinflammation and cell survival. Prostaglandins Leukot Essent Fatty Acids. 2013;88(1):127–9.
31. Lee JH, O’Keefe JH, Lavie CJ, Marchioli R, Harris WS. Omega-3 fatty acids for cardioprotection. In: Mayo Clinic Proceedings: 2008. Elsevier; 2008: 324–332.
32. Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, Smith DA, Berg AR, Stella PJ, Loprinzi CL. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer. 2011;19(1):1769–77.
33. Wen F, Zhou Y, Wang W, Hu QC, Liu YT, Zhang PF, Du ZD, Dai J, Li Q, Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis. Ann Oncol. 2013;24(3):490–5.
34. Bazan NG. The docosanoid neuroprotectin D1 induces homeostatic regulation of neuroinflammation and cell survival. Prostaglandins Leukot Essent Fatty Acids. 2013;88(1):127–9.
35. Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentschev T, Wender DB, Novotny PJ, Chitaley U, Alberts SR. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCTCG 04047. J Clin Oncol. 2011;29(4):421–7.
36. Piccolio J, Kolesar JM. Prevention and treatment of chemotherapy-induced peripheral neuropathy. Am J Health Syst Pharm. 2014;71(1):19–25.
37. Lee JS, Kim YJ, Jeon EK, Won HS, Cho Y-S, Ko YH. Effect of green tea extracts on oxaliplatin-induced peripheral neuropathy in rats. BMC Complement Altern Med. 2012;12(1):24.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit